Sarah Sammons/medicine.duke.edu
Jul 2, 2025, 17:27
Sarah Sammons: Dana-Farber’s Breast Oncology Center and Dr. Waks Debates Standard of Care in Stage II/III Her2+ Breast Cancer
Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on X:
“Happening Now.
Dana-Farber’s Breast Oncology Center and Dr. Waks debates standard of care in Stage II/III Her2+ Breast Cancer. Carboplatin addition to taxane HP does not improve pCR. EFS data still outstanding.
Neuropathy worse with weekly abraxane, HP for 18 weeks than TCHP.
What about Compass pCR? 12 weeks of taxane + HP in Stage II HER2+ BC.
pCR 43.8% overall: 63.7% ER-/HER2+, 32.5% ER+, HER2+.
Lower pCR rate with docetaxel versus weekly paclitaxel. EFS data is outstanding. No practice changing yet.
How many cycles 4 versus 6?
More cycles TCHP, higher pCR in TRAIN-3″
More posts featuring Sarah Sammons.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 2, 2025, 16:01
Jul 2, 2025, 15:53
Jul 2, 2025, 15:42
Jul 2, 2025, 15:32
Jul 2, 2025, 15:25
Jul 2, 2025, 14:52